Kiniksa Pharmaceuticals Q3 2025 Financial Results

Kiniksa Pharmaceuticals International, plc reported its third quarter 2025 financial results, highlighting significant growth in ARCALYST net product revenue, which reached $180.9 million, a 61% year-over-year increase. The company raised its 2025 ARCALYST net product revenue guidance to $670 - $675 million. Additionally, KPL-387 was granted Orphan Drug Designation for the treatment of pericarditis. Kiniksa's cash balance increased by $44.3 million to $352.1 million. The company remains on track for data from the Phase 2 dose-focusing portion of the KPL-387 Phase 2/3 recurrent pericarditis trial in the second half of 2026.